Literature DB >> 26466148

Drug Misuse in Adolescents Presenting to the Emergency Department.

Yaron Finkelstein1, Gautam Goel, Janine R Hutson, Jeffrey Armstrong, Carl R Baum, Paul Wax, Jeffrey Brent.   

Abstract

OBJECTIVES: Drug misuse is a disturbing, common practice among youth. One in 4 American adolescents reports consuming prescription medications without a clinical indication. We sought to explore current trends of drug misuse in adolescents.
METHODS: Using the 37 participating sites of the ToxIC (Toxicology Investigators Consortium) Case Registry, a cross-country surveillance tool, we conducted an observational cohort study of all adolescents (aged 13-18 years) who presented to emergency departments with drug misuse and required a bedside medical toxicology consultation between January 2010 and June 2013.
RESULTS: Of 3043 poisonings, 202 (7%) involved drug misuse (139 [69%] were males). Illicit drugs (primarily synthetic cannabinoids and "bath salts") were encountered in 101 (50%), followed by prescription medications (56 [28%]) and over-the-counter (OTC) drugs (51 [25%]). Dextromethorphan was the most commonly misused legal medication (24 [12%]). Polypharmacy exposure was documented in 74 (37%). One hundred sixty-three adolescents (81%) were symptomatic; of these, 81% had central nervous system impairments: psychosis (38%), agitation (30%), coma (26%), myoclonus (11%), and seizures (10%); and 66 (41%) displayed a specific toxidrome, most commonly sedative-hypnotic. Benzodiazepines were the most frequently administered medications (46%). Antidotes were administered to 28% of adolescents, primarily naloxone, physostigmine, N-acetyl-cysteine, and flumazenil. No deaths were recorded.
CONCLUSIONS: Adolescents presenting with drug misuse may be exposed to a wide range and combinations of therapeutics or illicit substances and frequently display central nervous system abnormalities, compromising the ability to obtain a reliable history. Frontline clinicians should maintain a high index of suspicion, as routine toxicology screenings fail to detect most contemporary misused legal and designer drugs.

Entities:  

Mesh:

Year:  2017        PMID: 26466148     DOI: 10.1097/PEC.0000000000000571

Source DB:  PubMed          Journal:  Pediatr Emerg Care        ISSN: 0749-5161            Impact factor:   1.454


  7 in total

1.  Adolescents' Misuse of Over-The-Counter Medications: The Need for Pharmacist-led Intervention.

Authors:  Olufunmilola Abraham; Jessica Chmielinski
Journal:  Innov Pharm       Date:  2018-10-15

Review 2.  The Toxicology Investigators Consortium Case Registry-the 2015 Experience.

Authors:  Lynn A Farrugia; Sean H Rhyee; Sharan L Campleman; Anne-Michelle Ruha; Timothy Weigand; Paul M Wax; Jeffrey Brent
Journal:  J Med Toxicol       Date:  2016-08-12

3.  Convulsant Effects of Abused Synthetic Cannabinoids JWH-018 and 5F-AB-PINACA Are Mediated by Agonist Actions at CB1 Receptors in Mice.

Authors:  Catheryn D Wilson; Sherrica Tai; Laura Ewing; Jasmine Crane; Taylor Lockhart; Ryochi Fujiwara; Anna Radominska-Pandya; William E Fantegrossi
Journal:  J Pharmacol Exp Ther       Date:  2018-11-12       Impact factor: 4.030

4.  Marketing Strategies Used to Promote Children's Medicine Sold on Internet Sites of Pharmaceutical Stores.

Authors:  Corey H Basch; Katherine J Roberts; Emily A Zagnit; Amairany Martinez
Journal:  J Community Health       Date:  2016-12

5.  Acute Rhabdomyolysis Following Synthetic Cannabinoid Ingestion.

Authors:  Demilade A Adedinsewo; Oluwaseun Odewole; Taylor Todd
Journal:  N Am J Med Sci       Date:  2016-06

6.  Is there such a thing as a 'lope' dope? Analysis of loperamide-related European Medicines Agency (EMA) pharmacovigilance database reports.

Authors:  Fabrizio Schifano; Stefania Chiappini
Journal:  PLoS One       Date:  2018-10-04       Impact factor: 3.240

7.  Transition of children with life-limiting conditions to adult care and healthcare use: a systematic review.

Authors:  Stuart W Jarvis; Daniel Roberts; Kate Flemming; Gerry Richardson; Lorna K Fraser
Journal:  Pediatr Res       Date:  2021-03-02       Impact factor: 3.756

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.